- Home
- PLXS vs VKTX Comparison
PLXS vs VKTX Comparison
Compare PLXS & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLXS
- VKTX
- Stock Information
- Founded
- PLXS 1979
- VKTX 2012
- Country
- PLXS United States
- VKTX United States
- Employees
- PLXS N/A
- VKTX N/A
- Industry
- PLXS Electrical Products
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- PLXS Technology
- VKTX Health Care
- Exchange
- PLXS Nasdaq
- VKTX Nasdaq
- Market Cap
- PLXS 3.7B
- VKTX 3.5B
- IPO Year
- PLXS 1986
- VKTX 2015
- Fundamental
- Price
- PLXS $137.26
- VKTX $26.00
- Analyst Decision
- PLXS Strong Buy
- VKTX Strong Buy
- Analyst Count
- PLXS 5
- VKTX 13
- Target Price
- PLXS $154.50
- VKTX $86.92
- AVG Volume (30 Days)
- PLXS 159.4K
- VKTX 9.0M
- Earning Date
- PLXS 10-22-2025
- VKTX 07-23-2025
- Dividend Yield
- PLXS N/A
- VKTX N/A
- EPS Growth
- PLXS 47.80
- VKTX N/A
- EPS
- PLXS 5.87
- VKTX N/A
- Revenue
- PLXS $4,025,169,000.00
- VKTX N/A
- Revenue This Year
- PLXS $3.54
- VKTX N/A
- Revenue Next Year
- PLXS $8.05
- VKTX $338.60
- P/E Ratio
- PLXS $23.32
- VKTX N/A
- Revenue Growth
- PLXS 2.31
- VKTX N/A
- 52 Week Low
- PLXS $103.43
- VKTX $18.92
- 52 Week High
- PLXS $172.89
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- PLXS 59.73
- VKTX 36.68
- Support Level
- PLXS $126.86
- VKTX $23.21
- Resistance Level
- PLXS $132.67
- VKTX $26.74
- Average True Range (ATR)
- PLXS 3.22
- VKTX 2.19
- MACD
- PLXS 0.61
- VKTX -1.68
- Stochastic Oscillator
- PLXS 89.35
- VKTX 14.67
About PLXS Plexus Corp.
Plexus Corp is a U.S based Electronic Manufacturing Services company that provides a range of services, from conceptualization and design to fulfilling orders and providing sustaining solutions, such as replenishment and refurbishment. The company's segments comprise AMER, APAC,ge and EMEA.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.